Equity Profile

BNTX

BioNTech SE

Health CareBiotechnology$23.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioNTech SE is a biotechnology company focused on developing and manufacturing innovative therapies, particularly in the field of mRNA technology. With a market cap of $23 billion, it plays a significant role in the healthcare sector, especially following its prominence in COVID-19 vaccine development.

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of profitability and will show how well the company is managing its costs.

$-2.08

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$156M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

In Q1 2026, BioNTech reported an EPS of $-2.28, which was better than analysts' expectations. However, the stock fell 3.88% the following day, indicating market disappointment despite the surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BioNTech to report a loss this quarter, with a consensus EPS of $-2.08. Revenue expectations are set at $156 million, reflecting ongoing challenges in the biotech sector.

Bull Case

If BioNTech can exceed revenue expectations and narrow its losses, it may signal a recovery in demand for its products, potentially boosting investor confidence.

Bear Case

A larger-than-expected loss or disappointing revenue could indicate ongoing struggles in the market, leading to further declines in stock value.

Key Metrics to Watch

EPS

$-2.08

Earnings per share is a critical indicator of profitability and will show how well the company is managing its costs.

Revenue

$156M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-2.08?

A smaller loss than expected could signal improved cost management and operational efficiency, potentially boosting investor sentiment.

How does the revenue of $156 million compare to previous quarters?

Revenue performance is crucial for understanding market demand and the company's ability to recover from past challenges.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate BioNTech's ability to recover from its recent losses, as the market is overly focused on short-term EPS figures rather than long-term growth potential.

Supporting Evidence

The company's innovative mRNA technology could drive future revenue growth beyond current estimates.

Recent partnerships and developments may not be fully reflected in the consensus revenue expectations.

Key Risk

If BioNTech reports revenue significantly above $156 million, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in assessing BioNTech's recovery trajectory and market position.

Bull Confirmed If

Revenue exceeding $156 million while narrowing losses could confirm a positive outlook.

Bear Confirmed If

A revenue figure significantly below $99 million or a larger loss than $-2.08 would confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests the stock could rise by around 2.09% on the first day, confirming a positive outlook.

In-Line / Cautious

A report in line with expectations may lead to muted reactions, as investors await further clarity on future guidance.

Miss

If the company misses expectations, the stock could drop by an average of 7.43%, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new partnerships or product developments that could drive future revenue.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into market demand for BioNTech's products beyond COVID-19.
4Guidance on future revenue expectations and product pipeline.
5Responses to competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of profitability and will show how well the company is managing its costs.

$-2.08

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$156M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

In Q1 2026, BioNTech reported an EPS of $-2.28, which was better than analysts' expectations. However, the stock fell 3.88% the following day, indicating market disappointment despite the surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BioNTech to report a loss this quarter, with a consensus EPS of $-2.08. Revenue expectations are set at $156 million, reflecting ongoing challenges in the biotech sector.

Bull Case

If BioNTech can exceed revenue expectations and narrow its losses, it may signal a recovery in demand for its products, potentially boosting investor confidence.

Bear Case

A larger-than-expected loss or disappointing revenue could indicate ongoing struggles in the market, leading to further declines in stock value.

Key Metrics to Watch

EPS

$-2.08

Earnings per share is a critical indicator of profitability and will show how well the company is managing its costs.

Revenue

$156M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-2.08?

A smaller loss than expected could signal improved cost management and operational efficiency, potentially boosting investor sentiment.

How does the revenue of $156 million compare to previous quarters?

Revenue performance is crucial for understanding market demand and the company's ability to recover from past challenges.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate BioNTech's ability to recover from its recent losses, as the market is overly focused on short-term EPS figures rather than long-term growth potential.

Supporting Evidence

The company's innovative mRNA technology could drive future revenue growth beyond current estimates.

Recent partnerships and developments may not be fully reflected in the consensus revenue expectations.

Key Risk

If BioNTech reports revenue significantly above $156 million, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in assessing BioNTech's recovery trajectory and market position.

Bull Confirmed If

Revenue exceeding $156 million while narrowing losses could confirm a positive outlook.

Bear Confirmed If

A revenue figure significantly below $99 million or a larger loss than $-2.08 would confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests the stock could rise by around 2.09% on the first day, confirming a positive outlook.

In-Line / Cautious

A report in line with expectations may lead to muted reactions, as investors await further clarity on future guidance.

Miss

If the company misses expectations, the stock could drop by an average of 7.43%, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new partnerships or product developments that could drive future revenue.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into market demand for BioNTech's products beyond COVID-19.
4Guidance on future revenue expectations and product pipeline.
5Responses to competitive pressures in the biotechnology sector.